References
- Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15: 2090–6
- von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658–67
- Glisson BS. Recurrent small cell lung cancer: Update. Semin Oncol 2003; 30: 72–8
- Tsao AS, Shin DM, Palmer JL, Lee JS, Glisson BS. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer 2004; 100: 2240–5
- Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, et al. Phase I study of docetaxel and topotecan in patients with solid tumors. Cancer Chemother Pharmacol 2000; 46: 442–8
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10